TY - JOUR
T1 - Early tolerance and late persistence as alternative drug responses in cancer
AU - Punzi, Simona
AU - Cittaro, Davide
AU - Gatti, Guido
AU - Crupi, Gemma
AU - Botrugno, Oronza A.
AU - Cartalemi, Antonino Alex
AU - Gutfreund, Alon
AU - Oneto, Caterina
AU - Giansanti, Valentina
AU - Battistini, Chiara
AU - Santacatterina, Giovanni
AU - Patruno, Lucrezia
AU - Villanti, Ilaria
AU - Palumbo, Martina
AU - Laverty, Daniel J.
AU - Giannese, Francesca
AU - Graudenzi, Alex
AU - Caravagna, Giulio
AU - Antoniotti, Marco
AU - Nagel, Zachary
AU - Cavallaro, Ugo
AU - Lanfrancone, Luisa
AU - Yap, Timothy A.
AU - Draetta, Giulio
AU - Balaban, Nathalie
AU - Tonon, Giovanni
N1 - Publisher Copyright:
© 2025. The Author(s).
PY - 2025/2/3
Y1 - 2025/2/3
N2 - Bacteria withstand antibiotic treatment through three alternative mechanisms: resistance, persistence or tolerance. While resistance and persistence have been described, whether drug-induced tolerance exists in cancer cells remains largely unknown. Here, we show that human cancer cells elicit a tolerant response when exposed to commonly used chemotherapy regimens, propelled by the pervasive activation of autophagy, leading to the comprehensive activation of DNA damage repair pathways. After prolonged drug exposure, such tolerant responses morph into persistence, whereby the increased DNA damage repair is entirely reversed. The central regulator of mitophagy PINK1 drives this reduction in DNA repair via the cytoplasmic relocalization of the cell identity master HNF4A, thus hampering HNF4A transcriptional activation of DNA repair genes. We conclude that exposing cancer cells to relevant standard-of-care antitumour therapies induces a pervasive drug-induced tolerant response that might be broadly exploited to increase the impact of first-line, adjuvant treatments and debulking in advanced cancers.
AB - Bacteria withstand antibiotic treatment through three alternative mechanisms: resistance, persistence or tolerance. While resistance and persistence have been described, whether drug-induced tolerance exists in cancer cells remains largely unknown. Here, we show that human cancer cells elicit a tolerant response when exposed to commonly used chemotherapy regimens, propelled by the pervasive activation of autophagy, leading to the comprehensive activation of DNA damage repair pathways. After prolonged drug exposure, such tolerant responses morph into persistence, whereby the increased DNA damage repair is entirely reversed. The central regulator of mitophagy PINK1 drives this reduction in DNA repair via the cytoplasmic relocalization of the cell identity master HNF4A, thus hampering HNF4A transcriptional activation of DNA repair genes. We conclude that exposing cancer cells to relevant standard-of-care antitumour therapies induces a pervasive drug-induced tolerant response that might be broadly exploited to increase the impact of first-line, adjuvant treatments and debulking in advanced cancers.
UR - http://www.scopus.com/inward/record.url?scp=85217864349&partnerID=8YFLogxK
U2 - 10.1038/s41467-024-54728-7
DO - 10.1038/s41467-024-54728-7
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 39900637
AN - SCOPUS:85217864349
SN - 2041-1723
VL - 16
SP - 1291
JO - Nature Communications
JF - Nature Communications
IS - 1
ER -